ADCITMER, an optimized antibody-drug conjugate to solve Merkel Cell carcinoma unmet medical need


Introduction – the problem:
Merkel cell carcinoma (MCC) is a rare and agressive skin cancer with a 5-year overall survival of 40%. Patients are first treated with platinum-based chemotherapies but there is no benefit on survival. Immune checkpoint inhibitors were a revolution in MCC treatment however, on long term, 75% of patients end up in therapeutic failure underlining the unmet medical need for this patient category.

The offer – the solution:
We propose to address this issue by developing ADCITMER, an antibody-drug conjugate (ADC) targeting a protein expressed on tumor cell surface. Using McSAF Inside bioconjugation technology – assuring homogeneity, stability and process reproducibility of the ADC from native monoclonal antibodies – we demonstrated the relevance of such a therapeutic strategy with nanomolar EC50 in vitro and with significative tumor growth delay in an aggressive xenograft tumor model in vivo. 
We brought together a team composed of experts in manufacturing, biologics development, and regulatory studies and a physician key opinion leader in Merkel Cell carcinoma with the aim to develop ADCITMER and reach a first-in-human phase 1 in 4 to 5 years. After this clinical POC, ADCITMER could be evaluated in other indications expressing the target of interest such as small cell lung cancer. We are currently searching for partners and investors to complete this project and eventually bring ADCITMER to the market and solve unmet medical needs.

Martin Camille

Poprzedni artykułBecome part of the ScanBalt Bioeconomy – lets implement great ideas
Następny artykułRynkowy launch – czyli jak wprowadzić na rynek innowacyjny produkt?